Skip to main
INCY

Incyte (INCY) Stock Forecast & Price Target

Incyte (INCY) Analyst Ratings

Based on 20 analyst ratings
Buy
Strong Buy 25%
Buy 20%
Hold 55%
Sell 0%
Strong Sell 0%

Bulls say

Incyte is poised to have strong market potential with its leading drug, Jakafi, in the rare blood cancer and graft versus host disease space, as well as a diverse portfolio of marketed drugs in rheumatoid arthritis, leukemia, and different types of cancer. The recent approval of Opzelura for atopic dermatitis and upcoming approval for vitiligo further solidifies Incyte's presence in the dermatology market. With positive early response data for its drug, Incyte looks to compete closely with Revolution Medicines' zoldonrasib and aims to preserve chemo delivery. Based on its current assets and promising pipeline, Incyte's valuation using a 9% discount rate and 2% terminal growth rate results in an EV of approximately $28B and a 12-month price target of $140 per share. Risks to consider include potential delays in securing approvals for late-stage candidates and failure to generate favorable data from ongoing programs.

Bears say

Incyte is showing declining revenues and a limited pipeline with only a few drugs in development. Additionally, the current success of their leading drug, Jakafi, is heavily reliant on partnerships with other companies like Novartis and Lilly. Their latest product launch, Opzelura, may provide some short-term revenue, but it is not enough to sustain long-term growth. Furthermore, recent CMS win and EU label momentum may improve their prospects, but it is not enough to offset the overall negative outlook for the company.

Incyte (INCY) has been analyzed by 20 analysts, with a consensus rating of Buy. 25% of analysts recommend a Strong Buy, 20% recommend Buy, 55% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Incyte and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Incyte (INCY) Forecast

Analysts have given Incyte (INCY) a Buy based on their latest research and market trends.

According to 20 analysts, Incyte (INCY) has a Buy consensus rating as of Sep 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $121.45, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $121.45, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Incyte (INCY)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.